4//SEC Filing
Christenson Johan 4
Accession 0000899243-20-018257
CIK 0001805890other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 4:02 PM ET
Size
14.7 KB
Accession
0000899243-20-018257
Insider Transaction Report
Form 4
Christenson Johan
Director
Transactions
- Conversion
Common Shares
2020-06-30+2,497,345→ 2,497,345 total(indirect: See Footnote) - Conversion
Class B Preferred Exchangeable Shares
2020-06-30−5,712,216→ 0 total(indirect: See Footnote)→ Common Shares (1,069,902 underlying) - Conversion
Common Shares
2020-06-30+1,069,902→ 3,567,247 total(indirect: See Footnote) - Purchase
Common Shares
2020-06-30$17.00/sh+240,000$4,080,000→ 3,807,247 total(indirect: See Footnote) - Conversion
Class A Preferred Exchangeable Shares
2020-06-30−13,333,333→ 0 total(indirect: See Footnote)→ Common Shares (2,497,345 underlying)
Footnotes (3)
- [F1]Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. The Class A Preferred Exchangeable Shares have no expiration date.
- [F2]The securities are held directly by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein.
- [F3]Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. The Class B Preferred Exchangeable Shares have no expiration date.
Documents
Issuer
Fusion Pharmaceuticals Inc.
CIK 0001805890
Entity typeother
Related Parties
1- filerCIK 0001488771
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 4:02 PM ET
- Size
- 14.7 KB